Influenza vaccination in immunocompromised patients: efficacy and safety

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Zhou H, Thompson WW, Viboud CG et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin. Infect. Dis.54(10),1427–1436 (2012).
  MedlineGoogle Scholar
• 2  Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit. Care Med.38(Suppl. 4),e91–e97 (2010).
  MedlineGoogle Scholar
• 3  Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med.161(3),441–446 (2001).
  Medline CASGoogle Scholar
• 4  Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis.10(8),521–526 (2010).
  MedlineGoogle Scholar
• 5  Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am. J. Med.102(3A),55–60; discussion 75–56 (1997).
  Medline CASGoogle Scholar
• 6  Nicholson KG, Wood JM, Zambon M. Influenza. Lancet362(9397),1733–1745 (2003).
  Medline CASGoogle Scholar
• 7  Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J. Acquir. Immune Defic. Syndr.34(3),304–307 (2003).
  MedlineGoogle Scholar
• 8  Martinez E, Marcos MA, Hoyo-Ulloa I et al. Influenza A H1N1 in HIV-infected adults. HIV Med.12(4),236–245 (2011).
  Medline CASGoogle Scholar
• 9  Perez CM, Dominguez MI, Ceballos ME et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. Aids24(18),2867–2869 (2010).
  MedlineGoogle Scholar
• 10  Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr. Opin. Organ Transplant.17(6),601–608 (2012).
  Medline CASGoogle Scholar
• 11  Cordero E, Perez-Romero P, Moreno A et al. Pandemic influenza A (H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin. Micorbiol. Infect.18(1),67–73 (2012).▪ This multicenter prospective study of 51 cases of influenza A (H1N1) pandemic infection showed that influenza was associated with significant mortality in solid-organ transplant recipients. A worse outcome was observed in patients with bacterial and fungal coinfection.
  Medline CASGoogle Scholar
• 12  Keane WR, Helderman JH, Luby J, Gailiunas P, Hull AR, Kokko JP. Epidemic renal transplant rejection associated with influenza A victoria. Proc. Clin. Dialysis Transplant Forum8,232–236 (1978).
  Medline CASGoogle Scholar
• 13  Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J. Heart Lung Transplant.21(5),559–566 (2002).
  MedlineGoogle Scholar
• 14  Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest119(4),1277–1280 (2001).
  Medline CASGoogle Scholar
• 15  Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA302(17),1872–1879 (2009).
  Medline CASGoogle Scholar
• 16  Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am. J. Transplant.2(3),287–291 (2002).
  MedlineGoogle Scholar
• 17  Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol. Blood Marrow Transplant.7(Suppl.) S5–S7 (2001).
  MedlineGoogle Scholar
• 18  Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant.32(1),73–77 (2003).
  Medline CASGoogle Scholar
• 19  Raboni SM, Stella V, Cruz CR et al. Laboratory diagnosis, epidemiology, and clinical outcomes of pandemic influenza A and community respiratory viral infections in southern Brazil. J. Clin. Microbiol.49(4),1287–1293 (2011).
  MedlineGoogle Scholar
• 20  Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis.39(9),1300–1306 (2004).
  MedlineGoogle Scholar
• 21  Reid G, Huprikar S, Patel G et al. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transplant Infect. Dis.15(5),487–492 (2013).
  Medline CASGoogle Scholar
• 22  Salliot C, Gossec L, Ruyssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology46(2),327–334 (2007).
  Medline CASGoogle Scholar
• 23  Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis.9(8),493–504 (2009).▪ Comprehensive review summarizing the existent data on the incidence and mortality rate of influenza infection among immunocompromised patients, as well as the efficacy and safety of the influenza vaccine in these populations.
  MedlineGoogle Scholar
• 24  Manuel O, Estabrook M, Practice ASTIDCO: RNA respiratory viruses in solid organ transplantation. Am. J. Transplant.13(Suppl. 4),212–219 (2013).
  Medline CASGoogle Scholar
• 25  Hobson D, Curry RL, Beare AS, Ward‑Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hygiene70(4),767–777 (1972).
  Medline CASGoogle Scholar
• 26  Mcelhaney JE, Ewen C, Zhou X et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine27(18),2418–2425 (2009).
  Medline CASGoogle Scholar
• 27  Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med.19(10),1305–1312 (2013).
  Medline CASGoogle Scholar
• 28  Fabbiani M, Di Giambenedetto S, Sali M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine29(16),2836–2839 (2011).
  Medline CASGoogle Scholar
• 29  Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am. J. Transplant.9(10),2346–2354 (2009).
  Medline CASGoogle Scholar
• 30  Fine AD, Bridges CB, De Guzman AM et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin. Infect. Dis.32(12),1784–1791 (2001).
  Medline CASGoogle Scholar
• 31  Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.131(6),430–433 (1999).
  Medline CASGoogle Scholar
• 32  Yamanaka H, Teruya K, Tanaka M et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr.39(2),167–173 (2005).▪ Study assessing the clinical efficacy of the influenza vaccine in HIV-infected patients, showing a protective effect of vaccination. The antibody response to influenza vaccine was related to CD4+ T-cell counts.
  Medline CASGoogle Scholar
• 33  Crum-Cianflone NF, Eberly LE, Duplessis C et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin. Infect. Dis.52(1),138–146 (2011).
  Medline CASGoogle Scholar
• 34  Gunthard HF, Wong JK, Spina CA et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis.181(2),522–531 (2000).
  Medline CASGoogle Scholar
• 35  Tebas P, Frank I, Lewis M et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. Aids24(14),2187–2192 (2010).
  Medline CASGoogle Scholar
• 36  Bickel M, Wieters I, Khaykin P et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. Aids24(9),F31–F35 (2010).
  Medline CASGoogle Scholar
• 37  Kroon FP, Van Dissel JT, De Jong JC, Zwinderman K, Van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3‑year study. Vaccine18(26),3040–3049 (2000).
  Medline CASGoogle Scholar
• 38  Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J. Heart Lung Transplant.30(6),685–690 (2011).
  MedlineGoogle Scholar
• 39  Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin. J. Am. Soc. Nephrol.6(5),1192–1197 (2011).
  MedlineGoogle Scholar
• 40  Sanchez-Fructuoso AI, Prats D, Naranjo P et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation69(3),436–439 (2000).
  Medline CASGoogle Scholar
• 41  Kimball P, Verbeke S, Tolman D. Influenza vaccination among heart transplant recipients. Transplantation Proc.33(1–2),1785–1786 (2001).
  Medline CASGoogle Scholar
• 42  Blumberg EA, Albano C, Pruett T et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin. Infect. Dis.22(2),295–302 (1996).
  Medline CASGoogle Scholar
• 43  Scharpe J, Evenepoel P, Maes B et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transplant.8(2),332–337 (2008).
  Medline CASGoogle Scholar
• 44  Briggs WA, Rozek RJ, Migdal SD et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann. Intern. Med.92(4),471–477 (1980).
  Medline CASGoogle Scholar
• 45  Burbach G, Bienzle U, Stark K et al. Influenza vaccination in liver transplant recipients. Transplantation67(5),753–755 (1999).
  Medline CASGoogle Scholar
• 46  Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir. J.18(6),971–976 (2001).
  Medline CASGoogle Scholar
• 47  Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Progress Transplant.14(4),346–351 (2004).
  MedlineGoogle Scholar
• 48  Cordero E, Aydillo TA, Perez-Ordonez A et al. Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients. Transplantation93(8),847–854 (2012).
  MedlineGoogle Scholar
• 49  Cordero E, Perez-Ordonez A, Aydillo TA et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am. J. Transplant.11(10),2205–2213 (2011).
  Medline CASGoogle Scholar
• 50  Keshtkar-Jahromi M, Argani H, Rahnavardi M et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am. J. Nephrol.28(4),654–660 (2008).
  Medline CASGoogle Scholar
• 51  Siegrist CA, Ambrosioni J, Bel M et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antiviral Ther.17(5),893–903 (2012).
  Medline CASGoogle Scholar
• 52  Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients. Transplantation94(6),630–636 (2012).
  Medline CASGoogle Scholar
• 53  Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am. J. Transplant.11(10),2020–2030 (2011).▪▪ Updated evidence-based recommendations for the use of influenza vaccine in solid-organ transplant recipients.
  Medline CASGoogle Scholar
• 54  Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am. J. Kidney Dis.54(1),112–121 (2009).
  Medline CASGoogle Scholar
• 55  Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant.11(1),1–5 (1993).
  Medline CASGoogle Scholar
• 56  Machado CM, Cardoso MR, Da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after. Bone Marrow Transplant36(10),897–900 (2005).
  Medline CASGoogle Scholar
• 57  Pauksen K, Linde A, Hammarstrom V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis.30(2),342–348 (2000).
  Medline CASGoogle Scholar
• 58  Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol. Blood Marrow Transplant.17(3),434–438 (2011).
  MedlineGoogle Scholar
• 59  Gandhi MK, Egner W, Sizer L et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant.28(8),775–781 (2001).
  Medline CASGoogle Scholar
• 60  Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol.34(2),272–279 (2007).
  Medline CASGoogle Scholar
• 61  Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann. Rheum. Dis.65(2),191–194 (2006).
  Medline CASGoogle Scholar
• 62  Elkayam O, Bashkin A, Mandelboim M et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum.39(6),442–447 (2010).
  Medline CASGoogle Scholar
• 63  Calmy A, Bel M, Nguyen A et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med.13(4),207–218 (2012).
  Medline CASGoogle Scholar
• 64  Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin. Infect. Dis.52(2),248–256 (2011).▪ Study evaluating the immunogenicity of the adjuvanted influenza A (H1N1) pandemic vaccine in immunocompromised patients. Kidney transplant recipients had lower, but appropriate, antibody responses compared with HIV-infected individuals and healthy controls.
  Medline CASGoogle Scholar
• 65  Manuel O, Humar A, Chen MH et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am. J. Transplant.7(11),2567–2572 (2007).
  Medline CASGoogle Scholar
• 66  Stanley SK, Ostrowski MA, Justement JS et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med.334(19),1222–1230 (1996).
  Medline CASGoogle Scholar
• 67  Fowke KR, D’amico R, Chernoff DN et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. Aids11(8),1013–1021 (1997).
  Medline CASGoogle Scholar
• 68  Yerly S, Wunderli W, Wyler CA et al. Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load. Aids8(10),1503–1504 (1994).
  Medline CASGoogle Scholar
• 69  Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am. J. Transplant.11(12),2751–2754 (2011).
  Medline CASGoogle Scholar
• 70  Katerinis I, Hadaya K, Duquesnoy R et al.De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am. J. Transplant.11(8),1727–1733 (2011).
  Medline CASGoogle Scholar
• 71  Baluch A, Humar A, Eurich D et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am. J. Transplant.13(4),1026–1033 (2013).
  Medline CASGoogle Scholar
• 72  Orlando G, Pariani E, Mazza F et al. Pandemic influenza vaccine in adult HIV-1-infected patients. Aids24(13),2142–2143 (2010).
  MedlineGoogle Scholar
• 73  Bickel M, Von Hentig N, Wieters I et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin. Infect. Dis.52(1),122–127 (2011).
  Medline CASGoogle Scholar
• 74  Durier C, Desaint C, Lucht F et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. Aids27(1),87–93 (2013).
  Medline CASGoogle Scholar
• 75  Bickel M, Lassmann C, Wieters I et al. Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls. HIV Clin. Trials14(4),175–184 (2013).
  Medline CASGoogle Scholar
• 76  Siegrist CA, Van Delden C, Bel M et al. Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS ONE7(7),e40428 (2012).
  Medline CASGoogle Scholar
• 77  Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med.361(25),2405–2413 (2009).
  Medline CASGoogle Scholar
• 78  Miraglia JL, Abdala E, Hoff PM et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS ONE6(11),e27214 (2011).
  Medline CASGoogle Scholar
• 79  Mohty B, Bel M, Vukicevic M et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica96(6),896–904 (2011).
  MedlineGoogle Scholar
• 80  Gabay C, Bel M, Combescure C et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheumatism63(6),1486–1496 (2011).
  Medline CASGoogle Scholar
• 81  Manuel O, Humar A, Berutto C et al. Low‑dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J. Heart Lung Transplant.30(6),679–684 (2011).
  MedlineGoogle Scholar
• 82  Morelon E, Pouteil Noble C, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine28(42),6885–6890 (2010).
  Medline CASGoogle Scholar
• 83  La Montagne JR, Fauci AS. Intradermal influenza vaccination – can less be more? N. Engl. J. Med.351(22),2330–2332 (2004).
  Medline CASGoogle Scholar
• 84  Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J. Immunol.191(6),3221–3231 (2013).
  Medline CASGoogle Scholar
• 85  Margine I, Krammer F, Hai R et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol.87(19),1043s6 (2013).
  Google Scholar
• 86  Gordon CL, Langan K, Charles PG et al. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin. Infect. Dis.52(3),422–426 (2011).
  Medline CASGoogle Scholar
• 87  Ye J, Shao H, Perez DR. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy4(2),175–186 (2012).
  CASGoogle Scholar
• 88  Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. Immunity to viruses: learning from successful human vaccines. Immunol. Rev.255(1),243–255 (2013).
  Medline CASGoogle Scholar